References
- Bowman P, Sulen A, Barbetti F, et al. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. Lancet Diabetes Endocrinol 6, 637–646, 2018.
- Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 13, 59, 2013.10.1186/1471-2431-13-59363747723601190
- Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life with the phenotype determined by genotype. Diabetologia 49, 1190–1197, 2006.10.1007/s00125-006-0246-z16609879
- Kobzova J, Vignerova J, Blaha P, Krejcovsky L, Riedlova J. The 6th nationwide anthropological survey of children and adolescents in the Czech Republic in 2001. Cent Eur J Public Health 12, 126–130, 2004.
- Misra S, Vedovato N, Cliff E, De Franco E, Hattersley AT, Ashcroft FM, Oliver NS. Permanent neonatal diabetes: combining sulfonylureas with insulin may be an effective treatment. Diabet Med 35, 1291–1296, 2018.10.1111/dme.1375829896782
- Myngheer N, Allegaert K, Hattersley AT, McDonald T, Kramer H, Ashcroft FM, Verhaeghe J, Mathieu C, Casteels K. Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes. Diabetes Care 37, 3333–3335, 2014.10.2337/dc14-1247589480425231897
- Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Sovik O, Polak M, Hattersley AT, Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355, 467–477, 2006.10.1056/NEJMoa06175916885550
- Stanik J, Gasperikova D, Paskova M, Barak L, Javorkova J, Jancova E, Ciljakova M, Hlava P, Michalek J, Flanagan SE, Pearson E, Hattersley AT, Ellard S, Klimes I. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab 92, 1276–1282, 2007.10.1210/jc.2006-2490761184917213273
- Stanik J, Dankovcikova A, Barak L, Skopkova M, Palko M, Divinec J, Klimes I, Gasperikova D. Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation and poor glycaemic control. Diabet Med 35, 386–391, 2018.10.1111/dme.1357529278452
- Stanik J, Barak L, Dankovcikova A, Valkovicova T, Skopkova M, Gasperikova D: Diabetes treatment in two pregnant women with permanent neonatal diabetes mellitus due to a KCNJ11 mutation. Diabet Med 2020. Online ahead of print.10.1111/dme.1436332634858
- Thurber BW, Carmody D, Tadie EC, Pastore AN, Dickens JT, Wroblewski KE, Naylor RN, Philipson LH, Greeley SA, US Neonatal Diabetes Working Group. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. Diabetologia 58, 1430–1435, 2015,10.1007/s00125-015-3593-9464152325877689